Reviewing Accelerate Diagnostics (AXDX) & Volcano (VOLC)

Volcano (NASDAQ: VOLC) and Accelerate Diagnostics (NASDAQ:AXDX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Volcano and Accelerate Diagnostics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Volcano 0 0 0 0 N/A
Accelerate Diagnostics 0 1 1 0 2.50

Accelerate Diagnostics has a consensus price target of $33.00, suggesting a potential upside of 16.81%.

Valuation & Earnings

This table compares Volcano and Accelerate Diagnostics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Volcano N/A N/A N/A ($0.74) N/A
Accelerate Diagnostics $250,000.00 6,260.20 -$66.37 million ($1.20) -23.54

Volcano has higher earnings, but lower revenue than Accelerate Diagnostics. Accelerate Diagnostics is trading at a lower price-to-earnings ratio than Volcano, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Volcano and Accelerate Diagnostics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Volcano -8.21% -10.48% -3.68%
Accelerate Diagnostics -3,085.36% -60.99% -57.85%

Institutional and Insider Ownership

47.9% of Accelerate Diagnostics shares are owned by institutional investors. 50.0% of Accelerate Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Volcano Company Profile

Volcano Corporation designs, develops, manufactures and commercializes a suite of precision guided therapy tools including intravascular ultrasound (IVUS) and fractional flow reserve (FFR) products. The Company markets its products to physicians, nurses and technicians who perform endovascular based coronary and peripheral interventional procedures in hospitals and to other personnel who make purchasing decisions on behalf of hospitals. The Company’s products consist of consoles that are marketed as stand-alone units or as units that can be integrated into a variety of hospital-based interventional surgical suites called catheterization laboratories, or cath labs. The Company has developed customized cath lab versions of these consoles. The Company sells products directly to customers in the United States, Japan, certain European markets and South Africa. The Company’s products include consoles, IVUS products, FFR products, Pioneer plus re-entry catheter and crux VCF system.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate PhenoTest BC Kit provides ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit.

Receive News & Ratings for Volcano Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Volcano and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply